# CG-549 Tablet Pharmacokinetics Study

> **NCT05393856** · PHASE1 · COMPLETED · sponsor: **CrystalGenomics, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CG-549

## Key facts

- **NCT ID:** NCT05393856
- **Lead sponsor:** CrystalGenomics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-23
- **Primary completion:** 2020-01-20
- **Final completion:** 2020-06-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05393856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05393856, "CG-549 Tablet Pharmacokinetics Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05393856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*